Roche launches Axelios 1 NGS platform
June 29, 2026—Roche has launched the Axelios 1, a next‑generation single-molecule sequencing platform powered by proprietary sequencing by expansion technology.
Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Thermo Fisher launches LabLink 360 QA software
June 26, 2026—Thermo Fisher Scientific has launched the Thermo Scientific LabLink 360 Quality Assurance software, designed to help clinical laboratories simplify quality control workflows, accelerate QC review and decision-making, improve visibility into QC performance, and manage QC operations.
Merck to acquire Bio-Techne for $11.3 billion
June 25, 2026—Merck (Darmstadt, Germany) has entered into a definitive agreement to acquire Minneapolis-based Bio-Techne Corp. for approximately $11.3 billion.
FDA-approved, at-home ColoSense test now available
June 24, 2026—Labcorp announced that ColoSense, an FDA-approved, at-home test for colorectal cancer screening, is now available for adults ages 45 to 85 who are at average risk for developing CRC.
Liaison Nes group A strep assay gets FDA clearance, CLIA waiver
June 23, 2026—Diasorin has received 510(k) clearance and CLIA waiver from the U.S. Food and Drug Administration for its group A streptococcus assay, for use on the Liaison Nes point-of-care molecular diagnostics platform.
Grifols launches next-gen immunohematology sample processing system
June 22, 2026—Grifols launched at the International Society of Blood Transfusion Congress (Kuala Lumpur, Malaysia, June 20–24) the Evanzys IH, a modular, fully automated, track-enabled system designed to streamline operations and reduce manual intervention in immunohematology sample processing.
Proscia launches fifth-generation Concentriq platform
June 19, 2026—Proscia introduced the fifth generation of its Concentriq platform, the most significant advancement to the platform in five years.
Diazyme Lp(a) molarity assay gets FDA 510(k) clearance
June 18, 2026—The FDA has granted 510(k) clearance for Diazyme Laboratories’ Lipoprotein(a) Molarity assay.
Roche CDx approved to assess PTEN protein in people with prostate cancer
June 15, 2026—Roche received FDA approval for the Ventana PTEN (SP218) RxDx assay, a qualitative immunohistochemistry companion diagnostic test for determining PTEN protein loss in tumors of patients with prostate adenocarcinoma.
RMT achieves SOC 2 type 2 certification
June 8, 2026—Remote Medical Technologies has achieved SOC 2 type 2 certification.